Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study

Background: Cytomegalovirus (CMV) infection can lead to significant morbidity and mortality in pediatric hematopoietic stem cell transplant recipients. Early detection of CMV infection is crucial for managing its impact. Aim: This study aims to evaluate the effectiveness of QuantiFERON-CMV ® (QF-CMV...

Full description

Saved in:
Bibliographic Details
Main Authors: Lina Souan, Rawad Rihani, Maher A. Sughayer
Format: Article
Language:English
Published: SAGE Publishing 2025-02-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/20406207251316680
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823865069348323328
author Lina Souan
Rawad Rihani
Maher A. Sughayer
author_facet Lina Souan
Rawad Rihani
Maher A. Sughayer
author_sort Lina Souan
collection DOAJ
description Background: Cytomegalovirus (CMV) infection can lead to significant morbidity and mortality in pediatric hematopoietic stem cell transplant recipients. Early detection of CMV infection is crucial for managing its impact. Aim: This study aims to evaluate the effectiveness of QuantiFERON-CMV ® (QF-CMV) and QuantiFERON-Monitor ® (QFM) tests in predicting CMV infection and graft-versus-host disease (GvHD) in pediatric hematopoietic stem cell transplant recipients to enhance patient outcomes and support personalized prevention strategies. Methods: The QF-CMV and QFM tests were used to predict CMV pp65 antigen and GvHD in 24 pediatric hematopoietic stem cell transplant recipients. Results: Data showed that positive CMV antigenemia (CMV-Ag) increased the risk of GvHD by 21.2%. QF-CMV and QFM were associated with CMV-Ag, with QF-CMV inversely predicting GvHD. Lymphocyte and neutrophil counts were positively linked to both tests. Conclusion: The findings suggest that QF-CMV and QFM tests could predict GvHD and CMV infection risk and help identify high-risk patients, contributing to personalized prevention strategies and improving CMV treatment. Despite the small sample size, this study is an essential proof of concept due to the unique patient population of pediatric bone marrow stem cell transplant recipients. Further multicenter studies are needed to validate these results.
format Article
id doaj-art-467a961fc551433f95d854dfc1e7faa3
institution Kabale University
issn 2040-6215
language English
publishDate 2025-02-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Hematology
spelling doaj-art-467a961fc551433f95d854dfc1e7faa32025-02-08T11:03:21ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152025-02-011610.1177/20406207251316680Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept studyLina SouanRawad RihaniMaher A. SughayerBackground: Cytomegalovirus (CMV) infection can lead to significant morbidity and mortality in pediatric hematopoietic stem cell transplant recipients. Early detection of CMV infection is crucial for managing its impact. Aim: This study aims to evaluate the effectiveness of QuantiFERON-CMV ® (QF-CMV) and QuantiFERON-Monitor ® (QFM) tests in predicting CMV infection and graft-versus-host disease (GvHD) in pediatric hematopoietic stem cell transplant recipients to enhance patient outcomes and support personalized prevention strategies. Methods: The QF-CMV and QFM tests were used to predict CMV pp65 antigen and GvHD in 24 pediatric hematopoietic stem cell transplant recipients. Results: Data showed that positive CMV antigenemia (CMV-Ag) increased the risk of GvHD by 21.2%. QF-CMV and QFM were associated with CMV-Ag, with QF-CMV inversely predicting GvHD. Lymphocyte and neutrophil counts were positively linked to both tests. Conclusion: The findings suggest that QF-CMV and QFM tests could predict GvHD and CMV infection risk and help identify high-risk patients, contributing to personalized prevention strategies and improving CMV treatment. Despite the small sample size, this study is an essential proof of concept due to the unique patient population of pediatric bone marrow stem cell transplant recipients. Further multicenter studies are needed to validate these results.https://doi.org/10.1177/20406207251316680
spellingShingle Lina Souan
Rawad Rihani
Maher A. Sughayer
Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study
Therapeutic Advances in Hematology
title Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study
title_full Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study
title_fullStr Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study
title_full_unstemmed Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study
title_short Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study
title_sort predicting cytomegalovirus infection and graft versus host disease using quantiferon cmv and monitor in pediatric transplants a proof of concept study
url https://doi.org/10.1177/20406207251316680
work_keys_str_mv AT linasouan predictingcytomegalovirusinfectionandgraftversushostdiseaseusingquantiferoncmvandmonitorinpediatrictransplantsaproofofconceptstudy
AT rawadrihani predictingcytomegalovirusinfectionandgraftversushostdiseaseusingquantiferoncmvandmonitorinpediatrictransplantsaproofofconceptstudy
AT maherasughayer predictingcytomegalovirusinfectionandgraftversushostdiseaseusingquantiferoncmvandmonitorinpediatrictransplantsaproofofconceptstudy